Comparative Pharmacology
Head-to-head clinical analysis: PAPA DEINE 3 versus ROXIPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAPA DEINE 3 versus ROXIPRIN.
PAPA-DEINE #3 vs ROXIPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen produces analgesia and antipyresis via central COX-2 inhibition and activation of descending serotonergic pathways. Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits ascending pain pathways and alters pain perception.
Roxiprin is a combination analgesic containing rofecoxib (a COX-2 selective NSAID) and paracetamol (acetaminophen, a centrally acting analgesic/antipyretic). Rofecoxib inhibits prostaglandin synthesis by selectively blocking cyclooxygenase-2, reducing pain and inflammation. Paracetamol inhibits cyclooxygenase in the central nervous system and modulates descending serotonergic pathways, providing analgesia and antipyresis.
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 12 tablets in 24 hours. Each tablet contains acetaminophen 300 mg, codeine phosphate 30 mg.
500 mg orally every 6 to 8 hours as needed for pain or fever; maximum 2000 mg per day.
None Documented
None Documented
Codeine: 2.5-3 hours; Acetaminophen: 2-3 hours; Morphine (active metabolite): 2-3 hours. In hepatic impairment, codeine half-life may extend to 4-6 hours.
2.5 hours (prolonged to 4-6 hours in hepatic impairment; no significant change in renal impairment)
Primarily renal (90% as glucuronide conjugates, 10% as morphine, codeine, and norcodeine). Biliary/fecal elimination accounts for <5%.
Renal (70% as unchanged drug, 20% as glucuronide conjugate); biliary/fecal (10%)
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination